Eyenovia, Inc. (NASDAQ:EYEN – Free Report) – Equities research analysts at Brookline Capital Management decreased their FY2023 earnings per share estimates for shares of Eyenovia in a note issued to investors on Monday, November 13th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of ($0.67) per share for the year, down from their previous estimate of ($0.65). Brookline Capital Management currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.68) per share. Brookline Capital Management also issued estimates for Eyenovia’s Q1 2024 earnings at ($0.19) EPS, Q2 2024 earnings at ($0.19) EPS, Q3 2024 earnings at ($0.19) EPS, FY2024 earnings at ($0.77) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at ($0.16) EPS and FY2027 earnings at $0.30 EPS.
Several other research analysts have also commented on EYEN. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Eyenovia in a research report on Wednesday, November 1st.
Eyenovia Trading Down 4.4 %
EYEN opened at $1.29 on Thursday. The firm has a market cap of $49.29 million, a price-to-earnings ratio of -1.95 and a beta of 1.75. The company has a current ratio of 5.73, a quick ratio of 5.73 and a debt-to-equity ratio of 1.25. Eyenovia has a 12 month low of $1.05 and a 12 month high of $5.85. The stock has a fifty day moving average price of $1.46 and a 200-day moving average price of $2.23.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Virtu Financial LLC increased its holdings in shares of Eyenovia by 27.8% in the first quarter. Virtu Financial LLC now owns 20,741 shares of the company’s stock valued at $73,000 after purchasing an additional 4,511 shares during the period. State Street Corp increased its holdings in shares of Eyenovia by 9.3% in the first quarter. State Street Corp now owns 61,617 shares of the company’s stock valued at $188,000 after purchasing an additional 5,217 shares during the period. Geode Capital Management LLC increased its holdings in shares of Eyenovia by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 260,067 shares of the company’s stock valued at $423,000 after purchasing an additional 6,056 shares during the period. Meitav Investment House Ltd. acquired a new position in shares of Eyenovia in the second quarter valued at about $1,104,000. Finally, Two Sigma Securities LLC acquired a new position in shares of Eyenovia in the second quarter valued at about $27,000. 16.66% of the stock is owned by institutional investors and hedge funds.
Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.
- Five stocks we like better than Eyenovia
- Find and Profitably Trade Stocks at 52-Week Lows
- Amazon, Target, Walmart in a race for fastest delivery
- Overbought Stocks Explained: Should You Trade Them?
- Palo Alto Networks: the one security stock to rule them all
- Stock Market Upgrades: What Are They?
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.